ORX750 in Clinical Trials: Exploring a Potential Treatment for Narcolepsy and Idiopathic Hypersomnia

What is ORX750?

ORX750 is an investigational medication being studied for the treatment of sleep disorders characterized by excessive daytime sleepiness. It is administered as an oral capsule and is currently in Phase 2 clinical trials1. The drug is designed to mimic the action of orexin, a natural protein in the brain that plays a critical role in regulating wakefulness and sleep cycles2.

Conditions Treated with ORX750

ORX750 is being studied for three specific sleep disorders12:

• Narcolepsy Type 1 (NT1) - A condition characterized by excessive daytime sleepiness and cataplexy (sudden loss of muscle strength triggered by strong emotions like laughter or surprise). People with NT1 may collapse or lose control of their muscles for short periods when experiencing strong emotions. They often have disrupted nighttime sleep as well.
• Narcolepsy Type 2 (NT2) - Similar to NT1 in that it causes excessive daytime sleepiness, but people with NT2 do not experience cataplexy. They still struggle to stay alert and attentive during daily activities.
• Idiopathic Hypersomnia (IH) - A condition where people feel excessively tired during the day despite sleeping normal or extended hours at night. People with IH may sleep for long periods, take extended naps, and find it particularly difficult to wake up. The term "idiopathic" means the cause is unknown.

All three conditions can significantly impact a person's ability to function at school, work, while driving, or during other daily activities due to the overwhelming sleepiness they cause2.

How ORX750 Works

ORX750 is designed to mimic the action of orexin, a protein in the brain that helps coordinate the wakefulness system2. Orexin is crucial for maintaining proper sleep-wake cycles.

In people with narcolepsy type 1, the brain cells that produce orexin are damaged or destroyed, leading to a deficiency of this important protein. By mimicking orexin's action, ORX750 aims to restore the normal function of the wakefulness system in the brain, helping patients feel more alert during the day2.

Clinical Studies on ORX750

ORX750 is currently being evaluated in clinical trials to determine its safety and effectiveness. Two significant studies are underway:

• CRYSTAL-1 Study - This is a Phase 2a, randomized, double-blind, placebo-controlled study (NCT06752668) designed to evaluate the safety, tolerability, pharmacokinetics (how the drug moves through the body), and pharmacodynamics (how the drug affects the body) of ORX750 in patients with narcolepsy and idiopathic hypersomnia2. In this study, participants are randomly assigned to receive either ORX750 or a placebo (a pill that looks identical but contains no active medication).
• Long-term Extension Study - This is an open-label, long-term extension study (NCT07096674) designed to provide information about the long-term safety, tolerability, and effectiveness of ORX7501. Participants who complete the parent study (CRYSTAL-1) may be eligible to continue receiving ORX750 in this extension study. Unlike the parent study, all participants in the extension study receive ORX750 (no placebo group).

Safety Monitoring During Clinical Trials

The safety of participants is a primary focus in these clinical trials. Several measures are being used to monitor safety12:

1. Treatment Emergent Adverse Events (TEAEs) - Researchers track any side effects that occur during treatment, including serious adverse events that might require medical attention.
2. Laboratory Tests - Blood and other laboratory tests are conducted regularly to check for any abnormal changes from baseline (before starting treatment).
3. Vital Signs - Measurements such as blood pressure, heart rate, temperature, and respiratory rate are monitored for any concerning changes.
4. Electrocardiograms (ECGs) - These tests monitor heart activity to detect any abnormal changes in heart rhythm or function.
5. Columbia-Suicide Severity Rating Scale (C-SSRS) - This assessment tool monitors for any suicidal thoughts or behaviors that might emerge during treatment.

How Effectiveness is Measured

The clinical trials are evaluating how well ORX750 works using several standardized measures12:

• Maintenance of Wakefulness Test (MWT) - This test measures a person's ability to stay awake in a quiet, dimly lit environment. The mean sleep latency (average time it takes to fall asleep) is calculated across multiple test trials. An increase in mean sleep latency would indicate improvement in the ability to stay awake.
• Epworth Sleepiness Scale (ESS) - This is a questionnaire that asks patients to rate their likelihood of falling asleep in various situations. A decrease in the ESS score would indicate improvement in daytime sleepiness.

In addition, researchers are measuring how ORX750 is processed by the body by looking at factors such as:

• Maximum Observed Plasma Concentration (Cmax) - The highest level of drug in the bloodstream after dosing.
• Time of Maximum Concentration (Tmax) - How long it takes to reach the maximum drug concentration in the blood.
• Area Under the Curve (AUC) - A measure of the total exposure to the drug over time.
• Steady State Measurements - Assessments of drug levels after regular dosing when concentrations have stabilized in the body.

These pharmacokinetic measurements help researchers understand how the drug moves through the body and how long it remains active, which is important for determining optimal dosing schedules12.